Search results
Results From The WOW.Com Content Network
Azathioprine, sold under the brand name Imuran, among others, is an immunosuppressive medication. [5] It is used for the treatment of rheumatoid arthritis , granulomatosis with polyangiitis , Crohn's disease , ulcerative colitis , and systemic lupus erythematosus , and in kidney transplants to prevent rejection .
How to Reset Female Hormones For Weight Loss. This article was reviewed by Craig Primack, MD, FACP, FAAP, MFOMA. Hormones can be helpful heroes, supporting the immune system and a healthy sleep ...
However, many are associated with an infamous side effect: weight gain. Luckily, some antidepressants are less likely to cause weight gain than others. In fact, there are even some antidepressants ...
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now.
Azathioprine (Prometheus' Imuran), is the main immunosuppressive cytotoxic substance. It is extensively used to control transplant rejection reactions. It is nonenzymatically cleaved to mercaptopurine, that acts as a purine analogue and an inhibitor of DNA synthesis. Mercaptopurine itself can also be administered directly.
Usually appetite enhancement is considered an undesirable side effect of certain drugs as it leads to unwanted weight gain, [3] [4] [5] but sometimes it can be beneficial and a drug may be prescribed solely for this purpose, especially when the patient is suffering from severe appetite loss or muscle wasting due to cystic fibrosis, anorexia ...
It could be that "people get on GLP-1s to lose weight, and as a consequence of the weight loss, feel better.” But it’s also possible that GLP-1s are benefiting the body in other ways, he says.
Over the course of 8 months, patient A gradually experienced more weight gain and sedation, and developed difficulty with their gait, stiffness, cogwheeling and dyskinetic ocular movements. A pharmacogenomics test later proved the patient had a CYP2D6 *1/*41, which has a predicted phenotype of IM and CYP2C19 *1/*2 with a predicted phenotype of ...